Navigation überspringen
Universitätsbibliothek Heidelberg

disk Markieren   Persönliche Notiz
Drucker
Andere Formate
Exportieren/Zitieren
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Goldinger, Simone M. [VerfasserIn]   i
 Buder-Bakhaya, Kristina [VerfasserIn]   i
 Lo, Serigne N. [VerfasserIn]   i
 Forschner, Andrea [VerfasserIn]   i
 McKean, Meredith [VerfasserIn]   i
 Zimmer, Lisa [VerfasserIn]   i
 Khoo, Chloe [VerfasserIn]   i
 Dummer, Reinhard [VerfasserIn]   i
 Eroglu, Zeynep [VerfasserIn]   i
 Buchbinder, Elizabeth I. [VerfasserIn]   i
 Ascierto, Paolo A. [VerfasserIn]   i
 Gutzmer, Ralf [VerfasserIn]   i
 Rozeman, Elisa A. [VerfasserIn]   i
 Hoeller, Christoph [VerfasserIn]   i
 Johnson, Douglas B. [VerfasserIn]   i
 Gesierich, Anja [VerfasserIn]   i
 Kölblinger, Peter [VerfasserIn]   i
 Bennannoune, Naima [VerfasserIn]   i
 Cohen, Justine V. [VerfasserIn]   i
 Kähler, Katharina C. [VerfasserIn]   i
 Wilson, Melissa A. [VerfasserIn]   i
 Cebon, Jonathan [VerfasserIn]   i
 Atkinson, Victoria [VerfasserIn]   i
 Smith, Jessica L. [VerfasserIn]   i
 Michielin, Olivier [VerfasserIn]   i
 Long, Georgina V. [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
 Weide, Benjamin [VerfasserIn]   i
 Haydu, Lauren E. [VerfasserIn]   i
 Schadendorf, Dirk [VerfasserIn]   i
 McArthur, Grant [VerfasserIn]   i
 Ott, Patrick A. [VerfasserIn]   i
 Blank, Christian [VerfasserIn]   i
 Robert, Caroline [VerfasserIn]   i
 Sullivan, Ryan [VerfasserIn]   i
 Hauschild, Axel [VerfasserIn]   i
 Carlino, Matteo S. [VerfasserIn]   i
 Garbe, Claus [VerfasserIn]   i
 Davies, Michael A. [VerfasserIn]   i
 Menzies, Alexander M. [VerfasserIn]   i
Titel:Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma
Titelzusatz:a retrospective multicentre analysis
Verf.angabe:Simone M. Goldinger, Kristina Buder-Bakhaya, Serigne N. Lo, Andrea Forschner, Meredith McKean, Lisa Zimmer, Chloe Khoo, Reinhard Dummer, Zeynep Eroglu, Elizabeth I. Buchbinder, Paolo A. Ascierto, Ralf Gutzmer, Elisa A. Rozeman, Christoph Hoeller, Douglas B. Johnson, Anja Gesierich, Peter Kölblinger, Naima Bennannoune, Justine V. Cohen, Katharina C. Kähler, Melissa A. Wilson, Jonathan Cebon, Victoria Atkinson, Jessica L. Smith, Olivier Michielin, Georgina V. Long, Jessica C. Hassel, Benjamin Weide, Lauren E. Haydu, Dirk Schadendorf, Grant McArthur, Patrick A. Ott, Christian Blank, Caroline Robert, Ryan Sullivan, Axel Hauschild, Matteo S. Carlino, Claus Garbe, Michael A. Davies, Alexander M. Menzies
Jahr:2022
Umfang:12 S.
Fussnoten:First published: 21 December 2021 ; Gesehen am 27.07.2022
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2022
Band/Heft Quelle:162(2022) vom: Feb., Seite 22-33
ISSN Quelle:1879-0852
Abstract:Introduction - Despite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the tumour microenvironment and does improve efficacy when used in combination with immunotherapy in lung cancer. Whether chemotherapy after checkpoint inhibitor failure has relevant activity in patients with metastatic melanoma is unknown. - Methods - Patients with metastatic melanoma treated with chemotherapy after progression on immunotherapy with checkpoint inhibitors were identified retrospectively from 24 melanoma centres. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety were examined. - Results - In total, 463 patients were treated between 2007 and 2017. Fifty-six per cent had received PD-1-based therapy before chemotherapy. Chemotherapy regimens included carboplatin + paclitaxel (32%), dacarbazine (25%), temozolomide (15%), taxanes (9%, nab-paclitaxel 4%), fotemustine (6%) and others (13%). Median duration of therapy was 7.9 weeks (0-108). Responses included 0.4% complete response (CR), 12% partial response (PR), 21% stable disease (SD) and 67% progressive disease (PD). Median PFS was 2.6 months (2.2, 3.0), and median PFS in responders was 8.7 months (6.3, 16.3), respectively. Twelve-month PFS was 12% (95% CI 2-15%). In patients who had received anti-PD-1 before chemotherapy, the ORR was 11%, and median PFS was 2.5 months (2.1, 2.8). The highest activity was achieved with single-agent taxanes (N = 40), with ORR 25% and median PFS 3.9 months (2.1, 6.2). Median OS from chemotherapy start was 7.1 months (6.5, 8.0). Subsequent treatment with checkpoint inhibitors achieved a response rate of 16% with a median PFS of 19.1 months (2.0-43.1 months). No unexpected toxicities were observed. - Conclusion - Chemotherapy has a low response rate and short PFS in patients with metastatic melanoma who have failed checkpoint inhibitor therapy, although activity varied between regimens. Chemotherapy has a limited role in the management of metastatic melanoma.
DOI:doi:10.1016/j.ejca.2021.11.022
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2021.11.022
 Volltext: https://www.sciencedirect.com/science/article/pii/S0959804921012429
 DOI: https://doi.org/10.1016/j.ejca.2021.11.022
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Anti-PD-1 antibodies
 Cancer
 Checkpoint inhibitors
 Chemotherapy
 Immunotherapy
 Melanoma
K10plus-PPN:181183129X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68947426   QR-Code
zum Seitenanfang

© Universitätsbibliothek HeidelbergMailImpressum / Datenschutz   Design